Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple sclerosis | EFO_0003885 | D009103 | G35 |
graft vs host disease | — | D006086 | D89.81 |
Code | Description |
---|---|
J7513 | Daclizumab, parenteral, 25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 3 | 4 | — | — | 7 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 3 | 4 | — | — | 7 |
Sclerosis | D012598 | — | — | — | 3 | 4 | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Daclizumab |
INN | daclizumab |
Description | Daclizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >3NFS:H|Light chain of Fab fragment of daclizumab
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAY
MELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
>3NFS:L|Heavy chain of Fab fragment of daclizumab
DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPD
DFATYYCHQRSTYPLTFGQGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE |
PDB | 3NFP, 3NFS |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201605 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00111 |
UNII ID | CUJ2MVI71Y (ChemIDplus, GSRS) |